{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:21:24Z","timestamp":1787239284367,"version":"build-2736575974"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40123-025-01240-w","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T09:02:05Z","timestamp":1758272525000},"page":"2673-2695","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Retinal and Choroidal Changes in Transthyretin-Related Amyloidosis Using Optical Coherence Tomography Modalities: A Systematic Review"],"prefix":"10.1007","volume":"14","author":[{"given":"Makan","family":"Ziafati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costanza","family":"Barresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Giuffr\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vittoria","family":"Cicinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"issue":"2","key":"1240_CR1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.coph.2005.10.005","volume":"6","author":"HJ Lachmann","year":"2006","unstructured":"Lachmann HJ, Hawkins PN. Systemic amyloidosis. Curr Opin Pharmacol. 2006;6(2):214\u201320.","journal-title":"Curr Opin Pharmacol"},{"issue":"4","key":"1240_CR2","first-page":"104","volume":"62","author":"G Merlini","year":"2004","unstructured":"Merlini G. Systemic amyloidosis: are we moving ahead. Neth J Med. 2004;62(4):104\u20135.","journal-title":"Neth J Med"},{"key":"1240_CR3","unstructured":"Violaine PB, Violaine P-B, G\u00e9rard S, G\u00e9rard S, G\u00e9rard S. Familial amyloid polyneuropathy. Lancet Neurol. 2011."},{"issue":"10038","key":"1240_CR4","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","volume":"387","author":"AD Wechalekar","year":"2016","unstructured":"Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387(10038):2641\u201354.","journal-title":"Lancet"},{"issue":"5","key":"1240_CR5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/13816810.2019.1666413","volume":"40","author":"M Latasiewicz","year":"2019","unstructured":"Latasiewicz M, Sala-Puigdollers A, Gonzalez-Ventosa A, Milla E, Adan Civera A. Multimodal retinal imaging of familial amyloid polyneuropathy. Ophthalmic Genet. 2019;40(5):407\u201320.","journal-title":"Ophthalmic Genet"},{"key":"1240_CR6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0074-7696(07)58003-4","volume":"258","author":"SJ Richardson","year":"2007","unstructured":"Richardson SJ. Cell and molecular biology of transthyretin and thyroid hormones. Int Rev Cytol. 2007;258:137\u201393.","journal-title":"Int Rev Cytol"},{"key":"1240_CR7","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2022.105313","volume":"155","author":"M Ueda","year":"2022","unstructured":"Ueda M. Transthyretin: its function and amyloid formation. Neurochem Int. 2022;155:105313.","journal-title":"Neurochem Int"},{"issue":"4","key":"1240_CR8","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/jns.12589","volume":"28","author":"L Frizziero","year":"2023","unstructured":"Frizziero L, Salvalaggio A, Cosmo E, Cipriani A, Midena E, Briani C. Ophthalmological involvement in wild-type transthyretin amyloidosis: a multimodal imaging study. J Peripher Nerv Syst. 2023;28(4):586\u201396.","journal-title":"J Peripher Nerv Syst"},{"issue":"21","key":"1240_CR9","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1212\/WNL.0000000000003362","volume":"87","author":"H Koike","year":"2016","unstructured":"Koike H, Ikeda S, Takahashi M, et\u00a0al. Schwann cell and endothelial cell damage in transthyretin familial amyloid polyneuropathy. Neurology. 2016;87(21):2220\u20139.","journal-title":"Neurology"},{"issue":"1","key":"1240_CR10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1212\/01.WNL.0000132966.36437.12","volume":"63","author":"H Koike","year":"2004","unstructured":"Koike H, Misu K, Sugiura M, et\u00a0al. Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology. 2004;63(1):129\u201338.","journal-title":"Neurology"},{"issue":"7","key":"1240_CR11","first-page":"387","volume":"15","author":"HA David","year":"2019","unstructured":"David HA, David A, David HA, et\u00a0al. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15(7):387\u2013404.","journal-title":"Nat Rev Neurol"},{"key":"1240_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/genes12060927","author":"AM Minnella","year":"2021","unstructured":"Minnella AM, Rissotto R, Maceroni M, et\u00a0al. Ocular involvement in hereditary transthyretin amyloidosis: a case series describing novel potential biomarkers. Genes. 2021. https:\/\/doi.org\/10.3390\/genes12060927.","journal-title":"Genes"},{"issue":"9","key":"1240_CR13","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","volume":"12","author":"MS Maurer","year":"2019","unstructured":"Maurer MS, Bokhari S, Damy T, et\u00a0al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12(9):e006075.","journal-title":"Circ Heart Fail"},{"key":"1240_CR14","doi-asserted-by":"crossref","first-page":"1174643","DOI":"10.3389\/fmed.2023.1174643","volume":"10","author":"M Rinaldi","year":"2023","unstructured":"Rinaldi M, Tranfa F, Chiosi F, et\u00a0al. OCT angiography indices and the choroidal vascularity index in wild-type transthyretin (TTR) amyloidosis (ATTRwt). Front Med (Lausanne). 2023;10:1174643.","journal-title":"Front Med (Lausanne)"},{"key":"1240_CR15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijcard.2020.02.072","volume":"312","author":"G Vergaro","year":"2020","unstructured":"Vergaro G, Solal AC, Emdin M. Wild type transthyretin amyloidosis: don\u2019t miss diagnosis! Int J Cardiol. 2020;312:96\u20137.","journal-title":"Int J Cardiol"},{"key":"1240_CR16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ajo.2017.09.001","volume":"183","author":"MM Reynolds","year":"2017","unstructured":"Reynolds MM, Veverka KK, Gertz MA, et\u00a0al. Ocular manifestations of familial transthyretin amyloidosis. Am J Ophthalmol. 2017;183:156\u201362.","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"1240_CR17","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s10072-012-1105-y","volume":"34","author":"M Luigetti","year":"2013","unstructured":"Luigetti M, Conte A, Del Grande A, et\u00a0al. TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients. Neurol Sci. 2013;34(7):1057\u201363.","journal-title":"Neurol Sci"},{"issue":"4","key":"1240_CR18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/bjo.81.4.295","volume":"81","author":"A Eiko","year":"1997","unstructured":"Eiko A, Eiko A, Yukio A, et\u00a0al. Ocular manifestations of familial amyloidotic polyneuropathy type I: long term follow up. British J Ophthalmol. 1997;81(4):295\u20138.","journal-title":"British J Ophthalmol"},{"issue":"3","key":"1240_CR19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/13506120209114820","volume":"9","author":"K Haraoka","year":"2002","unstructured":"Haraoka K, Ando Y, Ando E, et\u00a0al. Amyloid deposition in ocular tissues of patients with familial amyloidotic polyneuropathy (FAP). Amyloid. 2002;9(3):183\u20139.","journal-title":"Amyloid"},{"issue":"1","key":"1240_CR20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/13506129.2014.989318","volume":"22","author":"JM Beir\u00e3o","year":"2015","unstructured":"Beir\u00e3o JM, Malheiro J, Lemos C, et\u00a0al. Impact of liver transplantation on the natural history of oculopathy in Portuguese patients with transthyretin (V30M) amyloidosis. Amyloid. 2015;22(1):31\u20135.","journal-title":"Amyloid"},{"issue":"4","key":"1240_CR21","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/IAE.0000000000003378","volume":"42","author":"A Marta","year":"2022","unstructured":"Marta A, Marques JH, Ferreira A, Coelho J, Beir\u00e3o JM. Choroidal involvement in hereditary transthyretin amyloidosis patients. Retina. 2022;42(4):775\u201381.","journal-title":"Retina"},{"issue":"2","key":"1240_CR22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3109\/13506129.2015.1015678","volume":"22","author":"JM Beir\u00e3o","year":"2015","unstructured":"Beir\u00e3o JM, Malheiro J, Lemos C, Beir\u00e3o I, Costa P, Torres P. Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: a review of 513 cases. Amyloid. 2015;22(2):117\u201322.","journal-title":"Amyloid"},{"key":"1240_CR23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/TCRM.S219979","volume":"16","author":"M Luigetti","year":"2020","unstructured":"Luigetti M, Romano A, Di Paolantonio A, Bisogni G, Sabatelli M. Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care. Ther Clin Risk Manag. 2020;16:109\u201323.","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"1240_CR24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2018.1556156","volume":"26","author":"I Concei\u00e7\u00e3o","year":"2019","unstructured":"Concei\u00e7\u00e3o I, Damy T, Romero M, et\u00a0al. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid. 2019;26(1):3\u20139.","journal-title":"Amyloid"},{"key":"1240_CR25","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et\u00a0al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J. 2021;372:n71.","journal-title":"Br Med J"},{"issue":"9","key":"1240_CR26","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"key":"1240_CR27","unstructured":"NHLBI, NIH. Study quality assessment tools. Updated July 2021 [Available from: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"issue":"9","key":"1240_CR28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0275180","volume":"17","author":"S Kakihara","year":"2022","unstructured":"Kakihara S, Hirano T, Kitahara J, et\u00a0al. Application of optical coherence tomography angiography to assess systemic severity in patients with hereditary transthyretin amyloidosis. PLoS One. 2022;17(9):e0275180.","journal-title":"PLoS One"},{"issue":"1","key":"1240_CR29","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/13506129.2020.1827381","volume":"28","author":"JH Marques","year":"2021","unstructured":"Marques JH, Coelho J, Malheiro J, Pessoa B, Beir\u00e3o JM. Subclinical retinal angiopathy associated with hereditary transthyretin amyloidosis\u2014assessed with optical coherence tomography angiography. Amyloid. 2021;28(1):66\u201371.","journal-title":"Amyloid"},{"issue":"1","key":"1240_CR30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/IAE.0000000000003641","volume":"43","author":"J Ruiz-Medrano","year":"2023","unstructured":"Ruiz-Medrano J, Puertas M, Almaz\u00e1n-Alonso E, et\u00a0al. Ophthalmologic involvement in patients with hereditary transthyretin amyloidosis. Retina. 2023;43(1):49\u201356.","journal-title":"Retina"},{"key":"1240_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13030359","author":"M Maceroni","year":"2023","unstructured":"Maceroni M, Falsini B, Luigetti M, et\u00a0al. Ocular morpho-functional evaluation in ATTRv pre-symptomatic carriers: a case series. Diagnostics. 2023. https:\/\/doi.org\/10.3390\/diagnostics13030359.","journal-title":"Diagnostics"},{"issue":"1","key":"1240_CR32","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/13506129.2020.1827381","volume":"28","author":"JH Marques","year":"2021","unstructured":"Marques JH, Coelho J, Malheiro J, Pessoa B, Beir\u00e3o JM. Subclinical retinal angiopathy associated with hereditary transthyretin amyloidosis\u2013assessed with optical coherence tomography angiography. Amyloid. 2021;28(1):66\u201371.","journal-title":"Amyloid"},{"issue":"9","key":"1240_CR33","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1136\/bjophthalmol-2016-309481","volume":"101","author":"MV Cicinelli","year":"2017","unstructured":"Cicinelli MV, Rabiolo A, Marchese A, et\u00a0al. Choroid morphometric analysis in non-neovascular age-related macular degeneration by means of optical coherence tomography angiography. Br J Ophthalmol. 2017;101(9):1193\u2013200.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"1240_CR34","doi-asserted-by":"crossref","first-page":"519","DOI":"10.5505\/ejm.2021.59489","volume":"26","author":"K Yavuzer","year":"2021","unstructured":"Yavuzer K, Bozkurt B, Ozturk BT, Okudan S. The effect of age on subfoveal choroidal thickness in healthy subjects. East J Med. 2021;26(4):519\u201325.","journal-title":"East J Med"},{"issue":"4","key":"1240_CR35","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.joco.2017.06.004","volume":"29","author":"F Ghassemi","year":"2017","unstructured":"Ghassemi F, Mirshahi R, Bazvand F, Fadakar K, Faghihi H, Sabour S. The quantitative measurements of foveal avascular zone using optical coherence tomography angiography in normal volunteers. J Curr Ophthalmol. 2017;29(4):293\u20139.","journal-title":"J Curr Ophthalmol"},{"issue":"1","key":"1240_CR36","doi-asserted-by":"crossref","first-page":"10143","DOI":"10.1038\/s41598-018-28530-7","volume":"8","author":"H Shiihara","year":"2018","unstructured":"Shiihara H, Terasaki H, Sonoda S, et\u00a0al. Objective evaluation of size and shape of superficial foveal avascular zone in normal subjects by optical coherence tomography angiography. Sci Rep. 2018;8(1):10143.","journal-title":"Sci Rep"},{"issue":"5","key":"1240_CR37","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/archopht.1955.00930020666004","volume":"54","author":"HF Falls","year":"1955","unstructured":"Falls HF, Jackson J, Carey JH, Rukavina JG, Block WD. Ocular manifestations of hereditary primary systemic amyloidosis. AMA Arch Ophthalmol. 1955;54(5):660\u20134.","journal-title":"AMA Arch Ophthalmol"},{"issue":"3","key":"1240_CR38","first-page":"489","volume":"31","author":"AJ Dwork","year":"1990","unstructured":"Dwork AJ, Cavallaro T, Martone RL, Goodman DS, Schon EA, Herbert J. Distribution of transthyretin in the rat eye. Invest Ophthalmol Vis Sci. 1990;31(3):489\u201396.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"1240_CR39","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ophtha.2005.05.028","volume":"112","author":"T Kawaji","year":"2005","unstructured":"Kawaji T, Ando Y, Nakamura M, et\u00a0al. Ocular amyloid angiopathy associated with familial amyloidotic polyneuropathy caused by amyloidogenic transthyretin Y114C. Ophthalmology. 2005;112(12):2212.","journal-title":"Ophthalmology"},{"issue":"1","key":"1240_CR40","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0002-9394(99)80249-9","volume":"125","author":"KG Noble","year":"1998","unstructured":"Noble KG. Bilateral multifocal retinal arteriolar sheathing as the only ocular finding in hereditary amyloidosis. Am J Ophthalmol. 1998;125(1):111\u20133.","journal-title":"Am J Ophthalmol"},{"key":"1240_CR41","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ajo.2018.05.023","volume":"192","author":"A Rousseau","year":"2018","unstructured":"Rousseau A, Terrada C, Touhami S, et\u00a0al. Angiographic signatures of the predominant form of familial transthyretin amyloidosis (Val30Met Mutation). Am J Ophthalmol. 2018;192:169\u201377.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"1240_CR42","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0161-6420(82)34780-6","volume":"89","author":"MF Schwartz","year":"1982","unstructured":"Schwartz MF, Green WR, Michels RG, Kincaid MC, Fogle J. An unusual case of ocular involvement in primary systemic nonfamilial amyloidosis. Ophthalmology. 1982;89(4):394\u2013401.","journal-title":"Ophthalmology"},{"issue":"2","key":"1240_CR43","first-page":"99","volume":"34","author":"T Yoshinaga","year":"1994","unstructured":"Yoshinaga T, Nakazato M, Ikeda S, Ohnishi A. Three siblings homozygous for the transthyretin-Met30 gene in familial amyloidotic polyneuropathy\u2013evaluation of their clinical pictures with reference to those of other 10 cases reported. Rinsho Shinkeigaku Clin Neurol. 1994;34(2):99\u2013105.","journal-title":"Rinsho Shinkeigaku Clin Neurol"},{"issue":"2","key":"1240_CR44","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40120-020-00210-7","volume":"9","author":"H Koike","year":"2020","unstructured":"Koike H, Katsuno M. Transthyretin amyloidosis: update on the clinical spectrum, pathogenesis, and disease-modifying therapies. Neurol Ther. 2020;9(2):317\u201333.","journal-title":"Neurol Ther"},{"key":"1240_CR45","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117383","volume":"423","author":"J Alber","year":"2021","unstructured":"Alber J, Arthur E, Goldfarb D, et\u00a0al. The relationship between cerebral and retinal microbleeds in cerebral amyloid angiopathy (CAA): a pilot study. J Neurol Sci. 2021;423:117383.","journal-title":"J Neurol Sci"},{"issue":"1","key":"1240_CR46","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1212\/WNL.57.1.135","volume":"57","author":"E Ellie","year":"2001","unstructured":"Ellie E, Camou F, Vital A, et\u00a0al. Recurrent subarachnoid hemorrhage associated with a new transthyretin variant (Gly53Glu). Neurology. 2001;57(1):135\u20137.","journal-title":"Neurology"},{"issue":"3","key":"1240_CR47","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ana.410410305","volume":"41","author":"R Petersen","year":"1997","unstructured":"Petersen R, Goren H, Cohen M, et\u00a0al. Transthyretin amyloidosis: a new mutation associated with dementia. Ann Neurol. 1997;41(3):307\u201313.","journal-title":"Ann Neurol"},{"issue":"7","key":"1240_CR48","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.5665\/sleep.5958","volume":"39","author":"D Bodez","year":"2016","unstructured":"Bodez D, Guellich A, Kharoubi M, et\u00a0al. Prevalence, severity, and prognostic value of sleep apnea syndromes in cardiac amyloidosis. Sleep. 2016;39(7):1333\u201341.","journal-title":"Sleep"},{"issue":"4","key":"1240_CR49","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1046\/j.1442-9071.2002.00539.x","volume":"30","author":"AA Dunlop","year":"2002","unstructured":"Dunlop AA, Graham SL. Familial amyloidotic polyneuropathy presenting with rubeotic glaucoma. Clin Experiment Ophthalmol. 2002;30(4):300\u20132.","journal-title":"Clin Experiment Ophthalmol"},{"issue":"13","key":"1240_CR50","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","volume":"120","author":"C Rapezzi","year":"2009","unstructured":"Rapezzi C, Merlini G, Quarta CC, et\u00a0al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203\u201312.","journal-title":"Circulation"},{"issue":"10","key":"1240_CR51","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","volume":"126","author":"FL Ruberg","year":"2012","unstructured":"Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126(10):1286\u2013300.","journal-title":"Circulation"},{"issue":"1","key":"1240_CR52","doi-asserted-by":"crossref","first-page":"21090","DOI":"10.1038\/srep21090","volume":"6","author":"R Agrawal","year":"2016","unstructured":"Agrawal R, Gupta P, Tan K-A, Cheung CMG, Wong T-Y, Cheng C-Y. Choroidal vascularity index as a measure of vascular status of the choroid: measurements in healthy eyes from a population-based study. Sci Rep. 2016;6(1):21090.","journal-title":"Sci Rep"},{"issue":"4","key":"1240_CR53","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/mus.20821","volume":"36","author":"MD Benson","year":"2007","unstructured":"Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve Offic J Am Assoc Electrodiagn Med. 2007;36(4):411\u201323.","journal-title":"Muscle Nerve Offic J Am Assoc Electrodiagn Med"},{"issue":"6","key":"1240_CR54","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00415-014-7373-0","volume":"261","author":"V Plante-Bordeneuve","year":"2014","unstructured":"Plante-Bordeneuve V. Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy. J Neurol. 2014;261(6):1227\u201333.","journal-title":"J Neurol"},{"issue":"1","key":"1240_CR55","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/IAE.0000000000003291","volume":"42","author":"S Kakihara","year":"2022","unstructured":"Kakihara S, Hirano T, Kitahara J, et\u00a0al. Ocular angiographic features in Japanese patients with val30met hereditary transthyretin amyloidosis. Retina. 2022;42(1):210\u20135.","journal-title":"Retina"},{"issue":"2","key":"1240_CR56","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1399-0004.1992.tb03635.x","volume":"41","author":"L Jones","year":"1992","unstructured":"Jones L, Skara J, Cohen A, Harding J, Milunsky A, Skinner M. Familial amyloidotic polyneuropathy: a new transthyretin position 30 mutation (alanine for valine) in a family of German descent. Clin Genet. 1992;41(2):70\u20133.","journal-title":"Clin Genet"},{"issue":"7","key":"1240_CR57","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1212\/WNL.53.7.1498","volume":"53","author":"M Mascalchi","year":"1999","unstructured":"Mascalchi M, Salvi F, Pirini M, et\u00a0al. Transthyretin amyloidosis and superficial siderosis of the CNS. Neurology. 1999;53(7):1498.","journal-title":"Neurology"},{"issue":"4","key":"1240_CR58","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/lt.22019","volume":"16","author":"KR Muller","year":"2010","unstructured":"Muller KR, Padbury R, Jeffrey GP, et\u00a0al. Poor outcome after liver transplantation for transthyretin amyloid neuropathy in a family with an Ala36Pro transthyretin mutation: case report. Liver Transpl. 2010;16(4):470\u20133.","journal-title":"Liver Transpl"},{"key":"1240_CR59","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.exer.2013.02.005","volume":"110","author":"X Zou","year":"2013","unstructured":"Zou X, Dong F, Zhang S, Tian R, Sui R. Transthyretin Ala36Pro mutation in a Chinese pedigree of familial transthyretin amyloidosis with elevated vitreous and serum vascular endothelial growth factor. Exp Eye Res. 2013;110:44\u20139.","journal-title":"Exp Eye Res"},{"key":"1240_CR60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-019-1000-1","volume":"14","author":"M Waddington-Cruz","year":"2019","unstructured":"Waddington-Cruz M, Schmidt H, Botteman MF, et\u00a0al. Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series. Orphanet J Rare Dis. 2019;14:1\u20137.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"1240_CR61","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/joim.12383","volume":"278","author":"K Patel","year":"2015","unstructured":"Patel K, Hawkins P. Cardiac amyloidosis: where are we today? J Intern Med. 2015;278(2):126\u201344.","journal-title":"J Intern Med"},{"key":"1240_CR62","doi-asserted-by":"crossref","unstructured":"aus dem Siepen F, Hein S, Prestel S, et\u00a0al. Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy? Clin Res Cardiol 2019;108:1324\u201330.","DOI":"10.1007\/s00392-019-01467-1"},{"issue":"3","key":"1240_CR63","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/jns.12403","volume":"25","author":"F Wajnsztajn Yungher","year":"2020","unstructured":"Wajnsztajn Yungher F, Kim A, Boehme A, et\u00a0al. Peripheral neuropathy symptoms in wild type transthyretin amyloidosis. J Peripher Nerv Syst. 2020;25(3):265\u201372.","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"1240_CR64","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10072-022-06459-0","volume":"44","author":"M Campagnolo","year":"2023","unstructured":"Campagnolo M, Cacciavillani M, Cipriani A, et\u00a0al. Peripheral nerve involvement in wild-type transthyretin amyloidosis. Neurol Sci. 2023;44(1):351\u20134.","journal-title":"Neurol Sci"},{"issue":"9","key":"1240_CR65","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1001\/jamaophthalmol.2016.1889","volume":"134","author":"A Rousseau","year":"2016","unstructured":"Rousseau A, Cauquil C, Dupas B, et\u00a0al. Potential role of in vivo confocal microscopy for imaging corneal nerves in transthyretin familial amyloid polyneuropathy. JAMA Ophthalmol. 2016;134(9):983\u20139.","journal-title":"JAMA Ophthalmol"},{"key":"1240_CR66","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.amjmed.2022.01.008","volume":"135","author":"CD Fritz","year":"2022","unstructured":"Fritz CD, Blaney E. Evaluation and management strategies for GI involvement with amyloidosis. Am J Med. 2022;135:S20\u20133.","journal-title":"Am J Med"},{"issue":"Suppl 1","key":"1240_CR67","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10286-019-00628-6","volume":"29","author":"L Obici","year":"2019","unstructured":"Obici L, Suhr OB. Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis. Clin Auton Res. 2019;29(Suppl 1):55\u201363.","journal-title":"Clin Auton Res"},{"key":"1240_CR68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-9-61","volume":"9","author":"J Wixner","year":"2014","unstructured":"Wixner J, Mundayat R, Karayal ON, Anan I, Karling P, Suhr OB. Thaos: gastrointestinal manifestations of transthyretin amyloidosis-common complications of a rare disease. Orphanet J Rare Dis. 2014;9:1\u20139.","journal-title":"Orphanet J Rare Dis"},{"issue":"24","key":"1240_CR69","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","volume":"109","author":"CE Bulawa","year":"2012","unstructured":"Bulawa CE, Connelly S, Devit M, et\u00a0al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012;109(24):9629\u201334.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"36","key":"1240_CR70","doi-asserted-by":"crossref","first-page":"8654","DOI":"10.1021\/bi00151a036","volume":"31","author":"W Colon","year":"1992","unstructured":"Colon W, Kelly JW. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry. 1992;31(36):8654\u201360.","journal-title":"Biochemistry"},{"key":"1240_CR71","unstructured":"Mathew SM, Mathew SM, Jeffrey HS, et\u00a0al. Tafamidis Treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018."},{"key":"1240_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci10120952","author":"M Russo","year":"2020","unstructured":"Russo M, Gentile L, Toscano A, Aguennouz M, Vita G, Mazzeo A. Advances in treatment of ATTRv amyloidosis: state of the art and future prospects. Brain Sci. 2020. https:\/\/doi.org\/10.3390\/brainsci10120952.","journal-title":"Brain Sci"},{"issue":"11","key":"1240_CR73","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","volume":"260","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maia LF, da Silva AM, et\u00a0al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260(11):2802\u201314.","journal-title":"J Neurol"},{"key":"1240_CR74","doi-asserted-by":"crossref","unstructured":"Coelho T, Maia LF, Martins da Silva A, et\u00a0al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785\u201392.","DOI":"10.1212\/WNL.0b013e3182661eb1"},{"key":"1240_CR75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40120-016-0040-x","volume":"5","author":"T Coelho","year":"2016","unstructured":"Coelho T, Merlini G, Bulawa CE, et\u00a0al. Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis. Neurol Ther. 2016;5:1\u201325.","journal-title":"Neurol Ther"},{"issue":"1","key":"1240_CR76","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/13506129.2018.1554563","volume":"26","author":"JN Buxbaum","year":"2019","unstructured":"Buxbaum JN, Brannagan T III, Buades-Rein\u00e9s J, et\u00a0al. Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosis. Amyloid. 2019;26(1):10\u20134.","journal-title":"Amyloid"},{"key":"1240_CR77","doi-asserted-by":"crossref","unstructured":"Monteiro C, Martins da Silva A, Ferreira N, et\u00a0al. Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p. TTRV50M) amyloidosis patients. Amyloid. 2018;25(2):120\u20138.","DOI":"10.1080\/13506129.2018.1479249"},{"issue":"1","key":"1240_CR78","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, et\u00a0al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"9","key":"1240_CR79","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","volume":"369","author":"T Coelho","year":"2013","unstructured":"Coelho T, Adams D, Silva A, et\u00a0al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369(9):819\u201329.","journal-title":"N Engl J Med"},{"issue":"2","key":"1240_CR80","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40259-023-00577-7","volume":"37","author":"A Ioannou","year":"2023","unstructured":"Ioannou A, Fontana M, Gillmore JD. RNA targeting and gene editing strategies for transthyretin amyloidosis. BioDrugs. 2023;37(2):127\u201342.","journal-title":"BioDrugs"},{"issue":"1","key":"1240_CR81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2023.2232520","volume":"31","author":"S Ticau","year":"2024","unstructured":"Ticau S, Aldinc E, Polydefkis M, et\u00a0al. Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study. Amyloid. 2024;31(1):1\u201311.","journal-title":"Amyloid"},{"issue":"1","key":"1240_CR82","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1474-4422(20)30368-9","volume":"20","author":"D Adams","year":"2021","unstructured":"Adams D, Polydefkis M, Gonz\u00e1lez-Duarte A, et\u00a0al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurol. 2021;20(1):49\u201359.","journal-title":"Lancet Neurol"},{"key":"1240_CR83","unstructured":"David HA, David A, David A, et\u00a0al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018."},{"issue":"4","key":"1240_CR84","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, Adams D, Kristen A, et\u00a0al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis: analysis of the APOLLO study. Circulation. 2019;139(4):431\u201343.","journal-title":"Circulation"},{"issue":"2","key":"1240_CR85","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.23521","volume":"47","author":"MD Benson","year":"2013","unstructured":"Benson MD. Liver transplantation and transthyretin amyloidosis. Muscle Nerve. 2013;47(2):157\u201362.","journal-title":"Muscle Nerve"},{"issue":"3","key":"1240_CR86","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/lv.2000.6145","volume":"6","author":"OB Suhr","year":"2000","unstructured":"Suhr OB, Herlenius G, Friman S, Ericzon BG. Liver transplantation for hereditary transthyretin amyloidosis. Liver Transpl. 2000;6(3):263\u201376.","journal-title":"Liver Transpl"},{"issue":"3","key":"1240_CR87","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/lt.24058","volume":"21","author":"A Carvalho","year":"2015","unstructured":"Carvalho A, Rocha A, Lobato L. Liver transplantation in transthyretin amyloidosis: issues and challenges. Liver Transpl. 2015;21(3):282\u201392.","journal-title":"Liver Transpl"},{"issue":"3","key":"1240_CR88","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/01.TP.0000111516.60013.E6","volume":"77","author":"Y Ando","year":"2004","unstructured":"Ando Y, Terazaki H, Nakamura M, et\u00a0al. A different amyloid formation mechanism: de novo oculoleptomeningeal amyloid deposits after liver transplantation. Transplantation. 2004;77(3):345\u20139.","journal-title":"Transplantation"},{"key":"1240_CR89","unstructured":"Jo\u00e3o Melo B, Jo\u00e3o Melo B, Jorge M, et\u00a0al. Impact of liver transplantation on the natural history of oculopathy in Portuguese patients with transthyretin (V30M) amyloidosis. Amyloid. 2015."},{"issue":"3","key":"1240_CR90","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.exer.2005.02.003","volume":"81","author":"T Kawaji","year":"2005","unstructured":"Kawaji T, Ando Y, Nakamura M, et\u00a0al. Transthyretin synthesis in rabbit ciliary pigment epithelium. Exp Eye Res. 2005;81(3):306\u201312.","journal-title":"Exp Eye Res"},{"key":"1240_CR91","unstructured":"Ryuhei H, Ryuhei H, Takahiro K, et\u00a0al. Impact of liver transplantation on transthyretin-related ocular amyloidosis in Japanese patients. Arch Ophthalmol 2010."},{"issue":"5","key":"1240_CR92","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1600-0420.2007.01098.x","volume":"86","author":"O Sandgren","year":"2008","unstructured":"Sandgren O, Kjellgren D, Suhr OB. Ocular manifestations in liver transplant recipients with familial amyloid polyneuropathy. Acta Ophthalmol. 2008;86(5):520\u20134.","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"1240_CR93","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/ajt.17009","volume":"22","author":"HH Schmidt","year":"2022","unstructured":"Schmidt HH, Wixner J, Plant\u00e9-Bordeneuve V, et\u00a0al. Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation. Am J Transplant. 2022;22(6):1646\u201357.","journal-title":"Am J Transplant"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01240-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01240-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01240-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:42:03Z","timestamp":1760715723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01240-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":93,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1240"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01240-w","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Makan Ziafati, Costanza Barresi, Chiara Giuffr\u00e8, and Maria Vittoria Cicinelli have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study is based on previously published literature and does not involve any new investigations involving human participants or animals; therefore, ethical approval was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}